Henry C Fung| MM, lymphoma, leukemia & CART (@henrychihangfu1) ranks #7 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 29 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: MajesTEC-9, MajesTEC-3, PERSEUS. CMS Open Payments lists $105,712 in 2025 general payments.
At a Glance
- 14 posts naming a trial since ASH 2025
- 7 trials discussed by name
- Multiple Myeloma: US #7, Global #8 · 29 physicians engaged
- CMS Open Payments lists $105,712 in 2025 general payments.
This Month
What Henry C Fung| MM, lymphoma, leukemia & CART has posted in the last 30 days. Updated November 11, 2026.
More to watch at #ASH26! 📅 My schedule is attached. Thank you for flagging two important omissions from my preview: 🔹 MonumenTAL-6: Phase III Tec–Tal and Tal–Pom—PFS and OS benefits versus EPd/PVd. Major results, with safety and longer follow-up essential to interpretation. 🔹 AQUILA: Final survival analysis in the enrolled high-risk SMM population—7-year OS 87.8% vs 78.7% with daratumumab versus monitoring. Important findings to examine alongside risk definitions and treatment after progression. Two additional highlights: 🔹 PERSEUS: Long-term MRD outcomes and MRD-guided daratumumab maintenance discontinuation. 🔹 MajesTEC-5, Arm G: Early results with ramantamig, a BCMA × GPRC5D × CD3 trispecific, plus daratumumab/lenalidomide in transplant-eligible, newly diagnosed MM, followed by ramantamig/daratumumab maintenance without planned ASCT. This is a separate cohort from the original teclistamab-based cohorts incorporating ASCT. An increasingly crowded—and exciting—myeloma agenda in New Orleans! 🎷🦞🍹 📅 SEE THE SCHEDULE BELOW ⬇️ Our selected abstracts, dates, times, and locations—all times CST (New Orleans local time). Dr. Fun + G #MultipleMyeloma #mmsm #HemeTwitter
Who Amplifies Henry C Fung| MM, lymphoma, leukemia & CART
Physicians who reposted Henry C Fung| MM, lymphoma, leukemia & CART’s trial posts most often since ASH 2025.
- DC
Dr. Chokri Ben Lamine3 reposts - SA
Santhosh Ambika2 reposts - SI
soda_troubles, I have faith in Discord.2 reposts - JG
Julio García Suárez2 reposts - AM
Abdul Moiz Khan2 reposts - AK
Avinash Kumar Singh2 reposts - RB
Rahul Banerjee, MD, FACP2 reposts - JM
Jonas Moreno P2 reposts - AI
Ali ihsan OLUK1 repost - AH
Abul Hasan Shadali1 repost
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #7 | #8 | 67/100 | 29 | 46 | Full ranking |
Trials Henry C Fung| MM, lymphoma, leukemia & CART Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| MajesTEC-9 | 5 | #7 of 16 | May 31, 2026 |
| MajesTEC-3 | 4 | #6 of 15 | Sep 24, 2026 |
| PERSEUS | 3 | #5 of 10 | Sep 24, 2026 |
| AQUILA | 1 | #6 of 8 | Nov 6, 2026 |
| CERVINO | 1 | #11 of 11 | Sep 26, 2026 |
| MonumenTAL-6 | 1 | #4 of 4 | Jul 24, 2026 |
| CARTITUDE-4 | 1 | #4 of 9 | May 29, 2026 |
Henry C Fung| MM, lymphoma, leukemia & CART on MajesTEC-9
@YLeyfman Completely agree. Our intention was not to suggest that the role of bispecific therapy is to delay CAR-T. MajesTEC-9 demonstrates that teclistamab can be effective earlier in the disease course, but it does not answer the critical sequencing question. More importantly, "CAR-T"
MajesTEC-9 is one of the most important myeloma studies of the year. But after reviewing the eligibility criteria and baseline characteristics, I think several myths are emerging. ❌ It was not a triple-class refractory study. ❌ It was not a CAR-T comparison study. ❌ It https://t.co/O6rGHKPkHK
@RayWangonc Yes, I agree. Tec is a very solid 2L option. The unanswered questions are: • Fixed-duration therapy for favorable-risk patients? • CAR-T vs Tec-based platforms for high-risk first relapse? • Who still benefits from conventional salvage? MajesTEC-9 tells us Tec belongs
Henry C Fung| MM, lymphoma, leukemia & CART on MajesTEC-3
🚨 A model cannot fast-forward 15 years of follow-up. PERSEUS: projected median PFS 17.1 years. MajesTEC-3: projected median OS 18.5 years. These are extrapolations from approximately 4 and 3 years of median follow-up. Accuracy at the projected horizon remains unestablished. https://t.co/LWeCdf9hyo https://t.co/PPuqMJomFR
@Rfonsi1 @GKaurMD Interesting discussion, but I am not sure we can declare cilta-cel “dead” based on the current evidence. At EHA 2026, we saw encouraging subgroup analyses from MajesTEC-3 suggesting Dara/Tec may perform well even in functional high-risk and ultra-high-risk patients. That is good
🧬 T-Cell Fitness vs Target As EHA 2026 unfolds, one of the strongest signals in myeloma may not be which antigen we target. It may be when we engage the immune system. MajesTEC-3 (BCMA) and MonumenTAL-3 (GPRC5D) used different targets, yet both produced remarkably similar https://t.co/vLyyvVLgi1 https://t.co/RzTkftass8
Henry C Fung| MM, lymphoma, leukemia & CART on PERSEUS
🚨 A model cannot fast-forward 15 years of follow-up. PERSEUS: projected median PFS 17.1 years. MajesTEC-3: projected median OS 18.5 years. These are extrapolations from approximately 4 and 3 years of median follow-up. Accuracy at the projected horizon remains unestablished. https://t.co/LWeCdf9hyo https://t.co/PPuqMJomFR
Not all double-hit myeloma is the same! 🧬 Look across three very different studies: OPTIMUM/MUKnine, a multicenter phase II enriched for ultra-high-risk MM; MASTER, a smaller single-arm phase II enriched for HR disease; and PERSEUS, a large multicenter randomized phase III https://t.co/0YTr6O8ZSz https://t.co/r4BMXK14G7
One of the most important lessons from PERSEUS: 📌 MRD negativity is a milestone. 📌 Sustained MRD negativity is the destination. The next generation of studies may be judged less by CR rates and more by how many patients remain MRD-negative for years. #myeloma
Henry C Fung| MM, lymphoma, leukemia & CART on AQUILA
More to watch at #ASH26! 📅 My schedule is attached. Thank you for flagging two important omissions from my preview: 🔹 MonumenTAL-6: Phase III Tec–Tal and Tal–Pom—PFS and OS benefits versus EPd/PVd. Major results, with safety and longer follow-up essential to interpretation. 🔹 AQUILA: Final survival analysis in the enrolled high-risk SMM population—7-year OS 87.8% vs 78.7% with daratumumab versus monitoring. Important findings to examine alongside risk definitions and treatment after progression. Two additional highlights: 🔹 PERSEUS: Long-term MRD outcomes and MRD-guided daratumumab maintenance discontinuation. 🔹 MajesTEC-5, Arm G: Early results with ramantamig, a BCMA × GPRC5D × CD3 trispecific, plus daratumumab/lenalidomide in transplant-eligible, newly diagnosed MM, followed by ramantamig/daratumumab maintenance without planned ASCT. This is a separate cohort from the original teclistamab-based cohorts incorporating ASCT. An increasingly crowded—and exciting—myeloma agenda in New Orleans! 🎷🦞🍹 📅 SEE THE SCHEDULE BELOW ⬇️ Our selected abstracts, dates, times, and locations—all times CST (New Orleans local time). Dr. Fun + G #MultipleMyeloma #mmsm #HemeTwitter
Henry C Fung| MM, lymphoma, leukemia & CART on CERVINO
1/ Is etentamig replacing Tec/Elran? My take: no, but it adds a real option. Thoughts on #CERVINO from #IMS26👇 2/ Ph3, N=393, triple-class exposed, BCMA-naive, 2+ prior lines. Etentamig Q4W vs Kd/SVd/EPd. ORR 74 vs 46%, ≥CR 40 vs 7%, PFS HR 0.40. Median f/u 11.4 mo. 3/ The https://t.co/DmgXrddbeD
Henry C Fung| MM, lymphoma, leukemia & CART on MonumenTAL-6
Randomized trials answer the Q. they were designed to ask. MonumenTAL-6 demonstrated that Tal-Tec outperformed EPd/PVd in this study population 👍🏻 The next generation of questions remains: ❓Is fixed duration the reason for the remarkable efficacy, or simply the strategy that https://t.co/PMvscU8Qqz https://t.co/94xlsrC86w
Henry C Fung| MM, lymphoma, leukemia & CART on CARTITUDE-4
MajesTec - 9 & MajecTec - 3 & Cartitude - 4 - My interpretations. IMO: the real question is no longer Tec vs CAR-T. The real question is: which patient should receive which immunotherapy, and when? MajesTEC-9, CARTITUDE-4, and CARTITUDE-1 may be teaching us that sequencing https://t.co/EwWQNtwkJa https://t.co/YskpM9nwYM
Henry C Fung| MM, lymphoma, leukemia & CART’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
It’s MajesTEC-1,2,3,4,5,7,9… but I call it #MagicTec ✨🧬 An easier way to remember the journey: 🔹 Magic 1 Advanced / heavily pretreated disease 🔹 Magic 3 1st+ relapse, non-Dara refractory (teclistamab + Dara moving earlier) 🔹 Magic 4 Maintenance after transplant https://t.co/PJ61zpl6tn
Is Tec-Dara winning ? This network meta-analysis asks whether BCMA bispecifics are better than BCMA CAR-T in early relapse. We still don’t know. Tec–Dara’s 36-month PFS of 83.4% is extraordinary. But only 5% had prior anti-CD38 exposure, and Dara-refractory patients were https://t.co/nWOi0gih99
BCMA targeting continues to evolve. ⚔️🧬 We recently reviewed the MajesTEC universe. TODAY let’s focus on the DREAMM program and the long, unusual journey of Blenrep (belantamab mafodotin). From: 🧪 DREAMM-1 proof of concept ➡️ DREAMM-2 accelerated approval ➡️ DREAMM-3 https://t.co/jXjTRLLdrL https://t.co/q9RBfoy9JE
Dara–Iber–Dex: FDA approved. But where does it fit? 🤔 EXCALIBER is impressive: 41% MRD-negative CR at 10⁻⁵ vs 21% with DVd. But the fine print matters. Our common real-world first relapse is increasingly progression on Rev ± Dara maintenance. Rev-exposed: likely yes Rev-refractory / progression on Rev maintenance: unclear, subgroup data not yet disclosed Dara-exposed: very limited (~4%) Dara-refractory: no, excluded Dara + Rev dual-refractory: no supporting data And we still need to see the detailed MRD ascertainment/evaluable denominator. Iberdomide is clearly an active drug, and 41% MRD-negative CR is an impressive signal. But MRD is a path, not the destination. MRD negativity is an important clinical-trial endpoint and supported this accelerated FDA approval. What we still need is durability: PFS and ultimately OS. So despite FDA approval: Where Dara–Iber–Dex fits in the modern maintenance-failure patient remains TBD. Good drug. Impressive depth of response. Too many important unknowns to declare its place in the treatment algorithm yet. #MultipleMyeloma #Medtwitter
🩸🇪🇸 ESMO 2026 MYELOMA + MADRID GUIDE Myeloma in the morning. Tapas at night. 😆 📍 Madrid | Oct 23–27 ⭐ Essential session: Sat Oct 24, 08:30–10:00 Salamanca Auditorium, Hall 10 Three myeloma oral presentations: 1️⃣ 1454O—Bela-DRd in transplant-ineligible NDMM High MRD negativity sounds excellent—but what does belamaf truly add beyond DRd? We need durable PFS, tolerability and ocular-treatment burden—not another impressive MRD snapshot. 2️⃣ 1455O—Long-term BelaRd The important question is durability. Is frontline BCMA exposure justified when CAR-T and bispecific antibodies may be needed later? 3️⃣ 1456O—LBL-034, a new GPRC5D×CD3 bispecific in heavily pretreated RRMM Phase I and single-arm: promising, not practice-changing. Watch duration of response, infections, EMD activity and the familiar GPRC5D taste/skin/nail toxicities. BOTTOM LINE: ESMO myeloma is small but focused: ➡️ Belamaf moving earlier ➡️ Another GPRC5D bispecific moving forward ➡️ No phase III result likely to change practice immediately 🍖 NOW THE IMPORTANT SESSION: IBÉRICO! Easiest post-ESMO stop: 🥇 Cinco Jotas Padre Damián—excellent 100% ibérico de bellota and convenient after taking Metro Line 8 from IFEMA toward Nuevos Ministerios. For the complete Madrid experience: 🥓 Joselito’s Velázquez—destination-quality jamón 🍤 La Casa del Abuelo—gambas al ajillo 🍳 Casa Lucio/Huevos de Lucio—huevos rotos 🍺 Bodega de La Ardosa—tortilla, vermouth and old-Madrid atmosphere Scientific rule: Do not confuse MRD negativity with cure. Madrid rule: Do not confuse ordinary ham with jamón ibérico de bellota. 😆 #ESMO2026 #MultipleMyeloma
Industry Payments
CMS Open Payments · 2025 general payments
$105,712 across 68 payments